Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sun Yat-Sen Univ. RORγ compound 29
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
01
Overview
Sun Yat-Sen Univ. RORγ compound 29: sourced facts only. name: "These results clearly demonstrate that 29 is a highly potent and selective RORγ covalent inhibitor." [PMID:38227771]; target: "These results clearly demonstrate that 29 is a highly potent and selective RORγ covalent inhibitor." [PMID:38227771]; developer: "Balance-Based Drug Discovery Laboratory, School of Pharmaceutical Sciences, Sun Yat-Sen University, Guangzhou 510006, China." [PMID:38227771]
02
Targets
RORC (Retinoic acid receptor-related orphan receptor gamma)
Beyond the preview
Go deeper on Sun Yat-Sen Univ. RORγ compound 29.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sun Yat-Sen Univ. RORγ compound 29.